- Release Date: 13/11/15 10:13
- Summary: GENERAL: CVT: Derma Sciences Halts Phase III Clinical Trial
- Price Sensitive: No
- Download Document 1.96KB
CVT 13/11/2015 10:13 GENERAL NOT PRICE SENSITIVE REL: 1013 HRS Comvita Limited GENERAL: CVT: Derma Sciences Halts Phase III Clinical Trial Comvita's USA partner, Derma Sciences, Inc., in which Comvita owns 1.098m shares (4.3%), announced overnight that its clinical trial DSC 127 has been terminated. This clinical trial is unrelated to the sales programme of Medihoney products conducted by Derma Sciences. For your information, the attached Press Release from Derma Sciences to the market, explains. Ends For further information: Scott Coulter, Comvita Chief Executive, Ph. 021 386 988 Neil Craig, Comvita Chair, Ph. 021 731 509 About Comvita (www.comvita.co.nz) Comvita (NZX:CVT) is a global natural health company committed to the development of innovative products, backed by ongoing investment in scientific research. We are the world leaders in Manuka (leptospermum) honey and fresh-picked Olive Leaf Extract, which are at the core of the Comvita product range. We have approximately 50% of honey supply under direct ownership or control, with the balance of supply from long term contractual and partnership arrangements. Comvita pioneered the development and use of medical grade Manuka honey and was the first to receive FDA approval (2007). We partner with US wound care company Derma Sciences, Inc. (NASDAQ:DSCI), the global licensee for Medihoney(R) specialist wound care products, which are used in hospitals and medical centres around the world. Comvita's freshly picked Olive Leaf Extract is grown, harvested, extracted and bottled at the world's largest specialised olive leaf grove, with over one million olive trees. Comvita sells into more than 18 countries through a network of our own branded retail locations, online (seven country specific e-commerce websites) and third-party outlets. We have over 500 staff located in New Zealand, Australia, Hong Kong, Japan, South Korea, the United Kingdom and the USA. End CA:00273399 For:CVT Type:GENERAL Time:2015-11-13 10:13:49
- Forums
- NZX - By Stock
- CVT
- Ann: GENERAL: CVT: Derma Sciences Halts Phase III Clinical Trial
Ann: GENERAL: CVT: Derma Sciences Halts Phase III Clinical Trial
Featured News
Add CVT (NZSX) to my watchlist